Eleven years disease-free: Role of chemotherapy in metastatic BRCA2-related breast cancer

Nature Reviews Clinical Oncology

Volumn 6, Issue 8, 2009, Pages 488-492

  Huang, Fleur ^a   Kushner, Yael B ^a   Langleben, Adrian ^a   Foulkes, William D ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE; BRCA2 PROTEIN; CISPLATIN; MEGESTROL; PLATINUM COMPLEX; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; ANAMNESIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; INTRADUCTAL CARCINOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; PREMENOPAUSE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; AUTOTRANSPLANTATION; BONE TUMOR; BREAST TUMOR; GENETICS; LYMPH NODE METASTASIS; METASTASIS; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PEDIGREE; REVIEW; SEGMENTAL MASTECTOMY; TUMOR SUPPRESSOR GENE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; GENES, BRCA2; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; PEDIGREE; TRANSPLANTATION, AUTOLOGOUS;

EID: 70350034147     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.90     Document Type: Article

References (25)

1. Huang, F., alrefae, M., Langleben, a. & Roberge, d. Prophylactic cranial irradiation in advanced breast cancer: a case for caution. Int. J. Radiat. Oncol. Biol. Phys. 73, 752-758 (2009).
2. Peters, W. P. et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of caLGB 9082, sWOG 9114, and NcIc Ma-13. J. Clin. Oncol. 23, 2191-2200 (2005).
3. Berry, d. a. et al. BRcaPRO validation, sensitivity of genetic testing of BRca1/BRca2, and prevalence of other breast cancer susceptibility genes. J. Clin. Oncol. 20, 2701-2712 (2002).
4. Narod, s. a. & Foulkes, W. d. BRca1 and BRca2, 1994 and beyond. Nat. Rev. Cancer 4, 665 (2004).
5. Bane, a. L. et al. BRca2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am. J. Surg. Pathol. 31, 121-128 (2007).
6. Liebens, F. P., carly, B., Pastijn, a. & Rozenberg, s. Management of BRca1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur. J. Cancer 43, 238-257 (2007).
7. Foulkes, W. d. BRca1 and BRca2: chemosensitivity, treatment outcomes and prognosis. Fam. Cancer 5, 135-142 (2006).
8. Rennert, G. et al. clinical outcomes of breast cancer in carriers of BRca1 and BRca2 mutations. N. Engl. J. Med. 357, 115-123 (2007). (Pubitemid 47057729)
9. Pal, t., Permuth-Wey, J., Kapoor, R., cantor, a. & sutphen, R. Improved survival in BRca2 carriers with ovarian cancer. Fam. Cancer 6, 113-119 (2007).
10. Husain, a., He, G., Venkatraman, e. s. & spriggs, d. R. BRca1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 58, 1120-1123 (1998).
11. Petit, t. et al. are BRca1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers? [abstract]. ASCO Meeting Abstracts 25, 580 (2007).
12. Livingston, d. M. & silver, d. P. cancer: crossing over to drug resistance. Nature 451, 1066-1067 (2008).
13. decatris, M. P., sundar, s. & O'Byrne, K. J. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat. Rev. 30, 53-81 (2004).
14. Breakthrough Breast cancer & cancer Research uK Genetic Breast cancer trial: a randomised phase ii pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancer [online], http:// www.geneticbreastcancertrial.usilu.net/ Home.asp (2008).
15. Byrski, t. et al. Response to neo-adjuvant chemotherapy in women with BRca1-positive breast cancers. Breast Cancer Res. Treat. 108, 289-296 (2008).
16. Vogl, d. t. & stadtmauer, e. a. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant. 37, 985-987 (2006).
17. Berry, d. a. et al. High-dose chemotherapy with autologous stem-cell support versus standarddose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials [abstract 11]. Breast Cancer Res. Treat. 106 (Suppl. 1), s5 (2007).
18. tuma, R. s. end of high-dose chemotherapy for high-risk breast cancer patients? J. Natl Cancer Inst. 100, 618-619 (2008).
19. Hanrahan, e. O. et al. Randomized trial of highdose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106, 2327-2336 (2006).
20. Vredenburgh, J. J. et al. consolidation with highdose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol. Blood Marrow Transplant. 12, 195-203 (2006).
21. stemmler, H. J. et al. Lasting remission following multimodal treatment in a patient with metastatic breast cancer. Anticancer Drugs 16, 1135-1137 (2005).
22. Greenberg, P. a. et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14, 2197-2205 (1996).
23. coleman, R. e. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27, 165-176 (2001).
24. Gnant, M. et al. endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
25. Marchetti, P. et al. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. Ann. Oncol. 15 (Suppl. 1), I27-I34 (2004).